|Bid||15.96 x 600|
|Ask||26.41 x 100|
|Day's Range||22.01 - 22.26|
|52 Week Range||18.36 - 22.59|
|PE Ratio (TTM)||33.18|
|Forward Dividend & Yield||0.24 (1.08%)|
|1y Target Est||N/A|
Luminex Corporation (NASDAQ:LMNX) generated a below-average return on equity of 6.72% in the past 12 months, while its industry returned 10.71%. Though LMNX’s recent performance is underwhelming, it is usefulRead More...
Luminex Corp (NASDAQ:LMNX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
Luminex's (LMNX) extensive product line and rising revenues raise optimism. However, a challenging reimbursement scenario is likely to mar prospects.
On a per-share basis, the Austin, Texas-based company said it had a loss of 7 cents. Earnings, adjusted for pretax expenses, were 17 cents per share. The manufacturer of testing systems for biotechnology ...
How Is Accelerate Diagnostics Positioned at the Start of 2018? Accelerate Diagnostics’ (AXDX) Pheno System utilizes genotypic and phenotypic technology to identify infectious pathogens and perform antibiotic susceptibility tests (or AST), which determine if live bacterial or fungal cells are resistant or susceptible to a particular antimicrobial agent. The kit includes 140 assays for identification and susceptibility testing.
Abbott (ABT) appears to gain traction from the current integration and synergy achievement of St. Jude. Meanwhile, the company's recent closure of Alere takeover is another positive.
DexCom's (DXCM) collaborative agreements should bring in cash in the form of milestone payments and royalties, and help expand product portfolio.
Genomic Health's (GHDX) recent positive finds from a string of 10 trials on Oncotype DX Breast Recurrence Score test are likely to buoy investors' optimism.
Ecolab (ECL) continues to focus on investment in key businesses and bolt-on acquisitions to gain market traction and boost profits.
Genomic Health (GHDX) forges ahead with deals to strengthen hold in the high-potential prostate cancer therapeutics market.
Luminex Corporation (NASDAQ:LMNX) generated a below-average return on equity of 6.90% in the past 12 months, while its industry returned 10.18%. LMNX’s results could indicate a relatively inefficient operation toRead More...